Financials
Financial year 2025
LIGNAPHARMA from Mol, company number BE0840469861, closed financial year 2025 with a result of € 62,682 after tax. For that financial year LIGNAPHARMA recorded a gross margin of € 108,968 and equity of € 36,300. Compared with financial year 2024, the result moved from € 73,000 to € 62,682. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on December 17, 2025.
€ 36,300
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 62,682
▼ 14% vs 2024
Profit after tax over the fiscal year.
€ 121,722
▲ 32% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 62,682 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 8,830
▲ 260% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 105,737
▲ 28% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,088
▼ 69% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 125,544 | € 143,490 | € 130,165 | € 108,968 | ▼ 16% |
| Profit after taxes | € 62,946 | € 81,552 | € 73,000 | € 62,682 | ▼ 14% |
| Equity | € 36,300 | € 36,300 | € 36,300 | € 36,300 | |
| Total debts | € 180,511 | € 130,034 | € 197,035 | € 196,639 | |
| Cash | € 101,875 | € 51,239 | € 92,498 | € 121,722 | ▲ 32% |
| Land & buildings | - | - | € 23,976 | € 24,791 | ▲ 3% |
| Retained profit | € 3,300 | € 3,300 | € 3,300 | € 3,300 | |
| Dividend | € 62,946 | € 81,552 | € 73,000 | € 62,682 | ▼ 14% |
| Balance sheet total | € 234,704 | € 181,094 | € 250,537 | € 249,939 |
Key figures of LIGNAPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to LIGNAPHARMA?
What happened at LIGNAPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 62,682 (▼ 14% vs 2024). Source: NBB ↗
- New establishment in Lommel. KBO
- New establishment in Mol. KBO
- Start of the company according to the CBE. KBO
In short
From € 62,946 profit in 2022 to € 62,682 profit in 2025.
Paid € 98,674 in corporate taxes since 2022.
Best year ever: 2023, with € 81,552 profit.
Paid out € 280,180 in dividends to the owners in total.
A new publication or filing at LIGNAPHARMA? We notify you, reason included.
Follow LIGNAPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of IMMO UMBRIA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
LIGNAPHARMABehind LIGNAPHARMA is Immo Umbria BV. The shares are held by IMMO UMBRIA.
Directors
According to the 2025 annual accounts
Director · represented by Mary Romano
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Gompelbaan 114
2400 Mol
Lodewijk De Raetstraat 75
3920 Lommel
Active since 16 April 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0840.469.861
- VAT number
- BE 0840.469.861
- Registered office
- Gompelbaan 114, 2400 Mol
- Names & denominations
- LIGNAPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 October 2011
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Groothandel in andere voedingsmiddelen, neg
Handelsbemiddeling in de groothandel in voedings- en genotmiddelen
Vervaardiging van gehomogeniseerde voedingspreparaten en dieetvoeding
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren
Vervaardiging van geneesmiddelen
Vervaardiging van sportartikelen